AI-Assisted
Neuro-Oncology
Every year, thousands of brain tumors are missed because of the limitations of human cognition, denying patients the best possible care.
With automated detection and tracking, our mission is to make cancer diagnosis and treatment faster and more precise.
Detection and measurement
AFX-BM suggests the location of potential brain metastases on contrasted T1 brain MRI images.
Largest bidirectional diameters are automatically derived from the generated segmentation.
Identify findings
Individual findings are listed along with their size for easy navigation.
Once approved, each finding is assigned a unique lesion label, persistent across studies.
Longitudinal tracking
Approved findings corresponding to the same lesion are automatically associated between studies.
This association enables longitudinal tracking of individual lesion, facilitating estimation of clinical endpoints like RECIST or RANO-BM.
Comprehensive report
Detailed PDF report, concisely summarizing longitudinal data, including tables of tracked findings and graphical displays of lesion size progression.
News
In the heart of Montreal sits the non-profit organization Centech, a place that supports projects and startups with high growth potential – from conception right through to commercialization, which it says is thanks to a bold, collaborative, and passionate ecosystem.
As part of the Top 100 AI Startups, we were present at the 2023 ALL IN event to showcase our solution to the first edition of this important event dedicated to Canadian AI.
The tool developped by AFX Medical and its partners discovers small brain tumors that were missed by a team of researchers in radio-oncology from the University of Montreal Research Center (CRCHUM). Findings were published at the Society for Neuro-Oncology congress annual meeting held in Tampa Bay, June 2022. [FR]
The McGill Clinical Innovation Competition (CLIC) was launched in 2017 to inspire thinkers to develop solution that have a positive impact on healthcare. This award recognizes the best solution to an unmet clinical need for the care of a patient with the highest likelihood of success in being translated.
On this week’s show, we spoke with Jeremi Lavoie, CEO @ AFX Medical Jeremi Lavoie is the Co-Founder and CEO of AFX Medical. He was General Manager of, Car2go group since 2013. He was legal counsel for Enercon from May 2012 to May 2013. He worked as a litigation attorney at the Attorney General of Quebec from May 2007 to August 2010. AFX Medical is an applied AI software company specializing in the detection of brain lesions in neuroimaging for oncology. Every year, thousands of brain tumours are missed on brain imaging because of the limitations of human cognition, leading to delayed cancer treatment. With automated detection, its mission is to make cancer diagnosis and treatment faster and more precise.
Starting a business requires treading a path full of challenges, even more so when AI is involved. Thankfully, incubators are present to support young companies. [FR]
Research
Partners
